Heparan sulfate dependent phase separation of CCL5 and its chemotactic activity

Authors: Xiaolin Yu[1]†, Guangfei Duan[1]†, Pengfei Pei[1], Long Chen[1], Renji Gu[1], Wenrui Hu[1],

Hongli Zhang[1], Yan-Dong Wang[1], Lili Gong[2]; Lihong Liu[2]; Ting-Ting Chu[3]*, Jin-Ping Li[4,5]*

and Shi-Zhong Luo[1]*

Affiliations:

[1]State Key Laboratory of Chemical Resource Engineering, College of Life Science and

Technology, Beijing University of Chemical Technology, Beijing, 100029, China.

[2] Institute of Medical Science, China-Japan Friendship Hospital, Beijing, 100029, China.

[3]Greater Bay Biomedical InnoCenter, Shenzhen Bay Laboratory, Shenzhen, China.

[4]Beijing Advanced Innovation Centre for Soft Matter Science and Engineering, Beijing

University of Chemical Technology, Beijing, China

[5]Department of Medical Biochemistry and Microbiology, University of Uppsala, Uppsala,

Sweden

*Corresponding authors

Correspondence to Dr. Shi-Zhong Luo: luosz@mail.buct.edu.cn

Dr. Jin-ping Li: jin-ping.li@imbim.uu.se

Dr. Ting-Ting Chu: tingtingchu@szbl.ac.cn

† These authors contributed equally to this work.

Abstract: Secreted chemokines form concentration gradients in target tissues to control migratory directions and patterns of immune cells in response to inflammatory stimulation; however, how the gradients are formed is much debated. Heparan sulfate (HS) binds to chemokines and modulates their activities. In this study, we investigated the roles of HS in the gradient formation and chemoattractant activity of CCL5 that is known to bind to HS. CCL5 and heparin underwent liquid–liquid phase separation (LLPS) and formed gradient, which was confirmed using CCL5 immobilized on heparin-beads. The biological implication of HS in CCL5 gradient formation was established in CHO-K1 (wild type) and CHO-677 (lacking HS) cells by Transwell assay. The effect of HS on CCL5 chemoattractant activity was further proved by Transwell assay of human peripheral blood cells. Finally, peritoneal injection of the chemokines into mice showed reduced recruitment of inflammatory cells either by mutant CCL5 (lacking heparin binding sequence) or by addition of heparin to wild type CCL5. Our experimental data propose that co-phase separation of CCL5 with HS establishes a specific chemokine concentration gradient to trigger directional cell migration. The results warrant further investigation on other heparin binding chemokines and allows for a more elaborate insight into disease process and new treatment strategies.

Introduction

Gradients of signaling molecules are ubiquitous in embryonic development and cellular activities, modulating cell migration, proliferation, and survival(Griffith, Sokol et al., 2014, Yamamoto, Kambayashi et al., 2022, Yu, Burkhardt et al., 2009). Chemokines, belonging to a ~45-member family of small (8-12 kDa) proteins, are signaling molecules that can induce distinct cellular chemotaxis in response to inflammatory stimuli in a concentration-dependent

gradient(Weber, Hauschild et al., 2013). Chemokines play critical roles in regulating cell migration in a wide range of biological activities, e.g. developmental, homeostatic and inflammatory/pathological processes(Douglas, Dyer et al., 2015). It is established that chemokines are secreted from source cells and immobilized on glycosaminoglycans (GAGs) including heparan sulfate (HS) in the extracellular matrix(Proudfoot, Handel et al., 2003). The interaction of GAG-chemokine forms an immobilized gradient to provide direction to cell movement(Proudfoot, Johnson et al., 2017). Understanding how these chemokine gradients are formed and maintained is fundamental to identifying how they direct cell migration and proliferation. Straightforward molecular diffusion is often proposed as a possible mechanism(Kicheva, Pantazis et al., 2007, Schier & Needleman, 2009, Yu et al., 2009). However, it is assumed that more complicated mechanisms are involved, which remains to be elucidated.

CCL5 (also known as RANTES, for 'regulated on activation normal T cell expressed and secreted')(Roscic-Mrkic, Fischer et al., 2003) is an inflammatory chemokine that recruits a wide variety of leukocytes, including monocytes, granulocytes, and T cells, as well as mast cells and dendritic cells, through chemokine gradients(Roy, Mondal et al., 2015, Weber et al., 2013). CCL5 is composed 68 amino acids that reversibly self-assembles into high-MW oligomers, up to >600 kDa. This highly basic protein binds heparin with high affinity(Mulloy, 2005) and the oligomerization of CCL5 for the formation of gradient is modulated by GAGs on cell surface (Proudfoot et al., 2003).

Liquid–liquid phase separation (LLPS) driven by weak interactions between multivalent biomolecules was shown to be an important mechanism by which mesoscale structures of the condensates can form within the cell(Xue, Gong et al., 2019) and on the cell surface(Xue, Zhou

et al., 2022). Within phase-separated condensates, biomolecules are often mobile and interchanged between the dense and light phases. Based on reported information and our previous study, we have studied the implications of HS on CCL5 gradient formation and its chemotactic activity. Both in vitro and in vivo experiments demonstrate that co-phase separation of CCL5 with HS establishes specific chemokine concentration gradients for chemotactic activity.

Results

Co-phase separation of CCL5 and heparin

To illustrate the phase separation property of CCL5 in liquid, recombinant protein expressed in *E. coli* (**Figure 1—figure supplement 1A**)(Proudfoot, Power et al., 1996) was labeled with organic dye Cy3 (CCL5-Cy3) and mixed with heparin at different ratios. After 30 min formation of droplets was examined by fluorescence under confocal microscopy. At the ratio of 20:1 CCL5-Cy3 to heparin, few tiny droplets were detected, indicating phase separation. With increased ratio of CCL5-Cy3: heparin to 1:20 (20 μM CCL5-Cy3:1 μM heparin), large and round droplets were formed (**Figure 1A and B**). Further increases in heparin concentration (ratio 1:50) prevented droplet formation as a "reentrant" behavior. Since heparin is a linear repetitive structure with rich negative charges, the LLPS seems following a similar mechanism as RNA in the phase separation of many RNA binding proteins(Ghosh, Mazarakos et al., 2019). Longer incubation revealed that the droplets were dynamic and some became fused to form larger droplets (**Figure 1C**) that displayed a quick recovery speed in the fluorescence recovery after photobleaching (FRAP) (**Figure 1D**). The heparin-induced phase separation of CCL5 was attenuated at high salt concentrations as illustrated by incubation at different KCl concentrations in KMEI buffer (**Figure 1—figure supplement 2A and B**). In comparison, a mutant (A22K-CCL5) with higher positive charge density showed stronger interaction with heparin(Brandner,

Rek et al., 2009) and formed aggregates instead of phase separation with heparin in KMEI buffer (**Figure 1—figure supplement 2C and D**). These results indicated that heparin-induced LLPS of CCL5 was based on weak electrostatic interactions between the negatively charged polysaccharide and the basic protein of CCL5, while strong ionic interaction has abolished this effect.

An earlier study showed complex formation of CCL5 with a heparin disaccharide, which proposed the BBXB motif of CCL5 playing essential role in the interaction between the chemokine and the disaccharide (Shaw, Johnson et al., 2004). In light with this finding, we mutated [44]RKNR[47], a conserved positively charged BBXB motif of CCL5, to hydrophobic alanine motif [44]AANA[47] (Proudfoot, Fritchley et al., 2001), which is expected to reduce the interaction with heparin. As anticipated, the phase separation of the mutant [44]AANA[47]-CCL5 in solution containing heparin formed much smaller and fewer droplets in comparison to WT CCL5 (**Figure 1E, F**). The electrostatic interaction feature was further demonstrated by molecular docking analysis using a tetrasaccharide structure of heparin (**Figure 1—figure supplement 3A**). The results showed the docking of heparin tetrasaccharide into human CCL5, forming crucial electrostatic contacts at the CCL5 dimer interface, where it packed tightly against Arg 44, Lys45, Arg47 (**Figure 1—figure supplement 3A**). In comparison, binding free energy of heparin to the [44]AANA[47]-CCL5 mutant was significantly higher (**Figure 1—figure supplement 3B**).

Heparin dependent phase separation is one essential step for CCL5 gradient formation

To elucidate the intrinsic connection between the heparin-dependent phase separation of CCL5 and its chemotactic activity, we developed an in vitro diffusion assay in which purified His-CCL5-EGFP (400 ng/μL) (**Figure 1—figure supplement 1B**) was immobilized on

heparin-beads or on Ni-NTA-beads. In 96-well plates, the beads were embedded in the center of Matrigel(Helen P. Makarenkova, 2009) and incubated for 12 hr. Diffusion of the His-CCL5-EGFP was monitored by measuring fluorescence intensity along a line interval passing through the bead localized center. As shown in **Figure 2A**, His-CCL5-EGFP diffused a considerable distance away from the heparin-beads, forming a long and shallow gradient, whereas His-CCL5-EGFP did not diffuse from the Ni-NTA beads (**Figure 2B**). In comparison, [44]AANA[47]-CCL5 binding to the heparin-beads was significantly weaker and did not diffuse (**Figure 2A, right panel**). To exclude the potential effect of EGFP, we repeated the experiment using Cy3-tagged CCL5. In a similar manner, the heparin-beads bound CCL5-Cy3 diffused in Matrigel but not the Ni-NTA beads bound CCL5-Cy3 as revealed by 3D imaging (**Figure 2—figure supplement 1 and Figure 2—figure supplement 2**). These results suggest that heparin beads tethered CCL5 via phase separation, which enables rapid exchange with the external environment leading to diffusion and gradient formation; while the Ni-NTA beads bound CCL5 lacks phase separation, therefore no diffusion.

Next, to test whether the formed chemokine gradients of CCL5-heparin beads contribute to the chemotactic activity, we established an in vitro chemotaxis assay using Transwell (Proudfoot et al., 2003) in which CCL5 either in heparin-beads or in Ni-beads were placed in the lower chamber (**Figure 2C**) and THP-1 cells were placed in the upper chamber. Again, CCL5-heparin-beads showed robustly higher chemotactic activity (**Figure 2D**), while CCL5-Ni-NTA beads essentially did not induce chemotaxis. In comparison, [44]AANA[47]-CCL5-heparin-beads showed relatively weaker chemotactic activity than WT-CCL5-heparin-beads (**Figure 2D**). The dramatic difference in the chemotactic activity of CCL5 between immobilization on heparin-beads or Ni-NTA beads indicate that the chemotactic function is achieved by establishment of a functional gradient rather than just immobilization.

Heparan sulfate dependent CCL5 phase separation and its chemotactic activity

Having seen the functional roles of heparin in CCL5 gradient formation in solution and Matrigel, we wanted to find out whether heparan sulfate (HS) on the cell surface also can phase separate with CCL5 using a pair of well-established cell lines, CHO-K1 (wild type) and CHO-677 (mutant lacking HS). Co-incubation of CCL5-Cy3 with the cells resulted in strong signals on the cell surface of CHO-K1 revealed by confocal microscopy, indicating formation of puncta surrounding the cells (**Figure 3A**). However, CHO-677 completely lacked the signals. The finding was further verified by Z-stack scanning (**Figure 3B**). Fluorescence recovery of about 40% condensates after photobleaching (FRAP) indicates there is a liquidity of the condensates on CHO-K1(**Figure 3C**). These results indicated that CCL5 formed phase separation with HS on the CHO K1 cell surface, which was not possible in CHO-677 cells lacking HS.

In order to know whether the HS-dependent CCL5 phase separation is essential for the chemotactic activity of CCL5, we established a cell-based chemotaxis assay (**Figure 3D**). CHO-K1 cells along with CCL5 was placed in the lower chamber for 1 hr and THP-1 cells was seeded in the upper chamber, separated by a porous membrane. After incubation for 4 hr, THP-1 cells transmigrated into the lower chamber was quantified. The results revealed that both CCL5 alone and CHO-K1 alone had low chemotactic activity; in contrast, CHO-K1 in the presence of CCL5 showed significantly higher chemotactic activity **(Figure 3E)**. In the same line, the chemotactic activity of CCL5 was much lower when incubated with CHO-677 in the lower chamber. As it was found that higher proportion of heparin reduced phase separation of CCL5 (Figure 1A), we tested whether this is the case in cells. Indeed, addition of heparin in the incubation of CHO-K1 abolished the phase separation of CCL5-Cy3 on the cells surface (**Figure 3A**, lower panel), accordingly attenuated the chemotactic activity of CCL5 **(Figure 3E)**. When [44]AANA[47]-CCL5 was incubated with CHO-K1 cell, no obvious phase-separated condensates appeared on the cell surface (**Figure 3—figure supplement 1**), and consequently, [44]AANA[47]-CCL5 showed

reduced chemotactic activity when incubated with CHO-K1 (**Figure 3E**) in comparison with

WT CCL5. Thus, we may conclude that HS is essential on the CHO cell surface for phase

separation of CCL5 and its chemotaxis function.

Based on the observation that CCL5 forms a concentration gradient on heparin-beads where

heparin-driven phase separation enabled CCL5 diffuse, we hypothesized a similar scenario of

HS on cells, e.g., CCL5 was immobilized or condensed by HS on the cell surface through phase

separation, and gradually diffuse to form a gradient to guide cell migration. To test this

conjecture, we transfected the construct of CCL5-EGFP into CHO-K1. The cells were co-

cultured with Human Umbilical Vein Endothelial Cells (HUVEC)(Ynebrten, Barois et al.,

2015). Released CCL5-EGFP from CHO-K1 cells was readily taken up by nearby HUVEC cells,

formed bright phase-separated condensates on the cell surface (**Figure 4A and Figure 4—**

figure supplement 1A). With extended incubation, the condensates became fused (**Figure 4B**),

in a similar way of CCL5-heparin condensates in solution **(Figure 1C)**. The FRAP experiment

showed reasonable fluorescence recovery after photobleaching, indicating liquid-like properties

of the condensates on the cell surface (**Figure 4C**). To further illustrate the gradient formation

of the CCL5-EGFP condensates, we cultured HUVEC in Matrigel and embedded tiny amounts

(about 400 cells) of the CCL5-EGFP transfected CHO-K1 as a source of CCL5-EGFP. Confocal

microscopy monitoring found decreased concentration of CCL5-EGFP with increasing distance

of HUVEC from the source cells (CCL5-EGFP expressing CHO), confirming that CCL5-EGFP

established a gradient by phase separation on its target cells (**Figure 4D and E, Figure 4—**

figure supplement 1B and C). Further, both CHO-K1 and CHO-677 transfected with CCL5-

EGFP were analyzed on the same setting. The results show that a gradient was formed in CHO-

K1 cells when co-cultured with CCL5-EGFP transfected CHO-K1 in Matrigel, while CHO-677

failed to form the concentration gradient (**Figure 4—figure supplement 1D**). Furthermore, the

chemotactic activity was demonstrated by placing CCL5-EGFP transfected CHO-K1 in a lower

chamber and THP-1 in the upper chamber. Counting the transmigrated THP-1 cells showed that the transfected CHO-K1 had stronger chemotactic activity compared with WT-CHO-K1(**Figure 4F**).

Ex vivo and in vivo demonstration of HS-dependent chemotactic activity of CCL5

To further verify our findings, we placed HUVEC or CHO cells in the lower chamber in the presence of CCL5 and human peripheral blood cells (PBMC) in the upper chamber of the Transwell device to detect transmigration of the inflammatory cells. Quantification of the transmigrated cells into the lower chamber after incubation for 4 hr revealed that neither CCL5 alone nor CHO-677 in the presence of CCL5 showed substantial chemotactic activity; in contrast, HUVEC and CHO-K1 in the presence of CCL5 showed significantly higher chemotactic activity. It should be pointed out that the total PBMC in the 3 blood samples varied dramatically, resulting in the great deviations in the number of transmigrated cells of each sample. Nevertheless, the trend of chemotactic activity under the different conditions is consistent in all samples (**Figure 5**).

To verify our findings in vivo, wild-type or mutant CCL5 was injected into the peritoneal cavity of Balb/c mice and peritoneal cells recruitment was monitored(Proudfoot et al., 2003) . Wild-type CCL5 induced a robust increase of total cells in the peritoneal lavage to a level approximately 4-fold over the saline control (**Figure 6**). In comparison, though ^{44}AANA^{47}-CCL5 group had a higher cell number than saline control, the recruited cells was much less than CCL5. Heparin (1 mg/mL) co-injected with wild-type CCL5 attenuated the recruitment of inflammatory cells, which, again, can be ascribed to the competitive interaction with endogenous HS in binding to CCL5. Overall, these results demonstrate that the phase separation of CCL5 with HS indeed contribute to chemotaxis function of CCL5 in vivo.

Discussion

It has been suggested that an important component of the chemokine-signaling is formation

of a haptotactic gradient through immobilization of chemokines on cell surface

glycosaminoglycans (GAGs)(Helen P. Makarenkova, 2009). Interactions with GAGs facilitate

gradient formation of chemokine, providing directional cues for migrating cells. Heparan sulfate

(HS) is one member of the GAGs family and ubiquitously expressed on the cells surface of

endothelial and epithelial cells, forming glycocalyx(Simon Davis & Parish, 2013). It is known

that HS (and its analogue heparin) binds to a broad spectrum of cytokines, functioning as a co-

receptor to mediate signaling activity of the cytokines(Xie & Li, 2019). Several inflammatory

chemokines, including CCL5, bind to HS/heparin(Proudfoot et al., 2003); however, the

molecular mechanisms of HS in CCL5 - induced chemotactic activity has not been reported.

Phase separation is a common mechanism for protein assembly and compartmentalization,

and it contributes to a variety of cellular processes, including the formation of membraneless

organelles, signaling complexes, the cytoskeleton and numerous other supramolecular

assemblies(Hyman, Weber et al., 2014, Zbinden, Pérez-Berlanga et al., 2020). Emerging

evidence indicates that biomolecules in phase-separated liquid droplets are mobile and

transitorily interact with surrounding molecules(Nakashima, Vibhute et al., 2019). Most of CC

chemokines are found to occur oligomerization in vivo, which may be modulated by

GAGs(Hoogewerf, Kuschert et al., 1997). However, the exceptional species of CCL7 is present

at monomer, and has multiple glycosaminoglycan-binding epitopes, enabling it to functions as

a non-oligomerizing chemokine(Salanga, Dyer et al., 2014). In comparison, CXCL4 (Platelet

Factor 4) binds strongly to heparin(Shi, Zhao et al., 2023) and heparan sulfate(Horton, Su et al.,

2021), leading to formation of oligomers and aggregates. It should be interesting to examine

whether these chemokines also undergo phase separation and to find out whether LLPS is

controlled by oligomerization.

Earlier study reported that the conserved and positively charged BBXB motif in the CC

chemokines is the key to interact with negatively charged GAGs through multivalent weak ionic

interactions(Liang, Wenguang et al., 2016). Structural study revealed that the basic amino acids

R44, K45, and R47 create two positively charged regions on the interface of CCL5 dimer,

facilitating the interaction with heparin(Lortat-Jacob, Grosdidier et al., 2002). Based on above

findings, using our established liquid-liquid phase separation (LLPS) method, we demonstrated

that CCL5 phases separate on the cell surface via a heparan sulfate (HS) dependent mechanism,

which is required for CCL5 chemotaxis. Mutations on the basic amino acids R44, K45, and R47

resulted in loosing binding of CCL5 to heparin beads, accordingly, lost its chemotactic activity.

This finding also supports the fact that the phase separation of CCL5 with HS is mediated by

weak electrostatic interactions, which facilitates the diffusion of CCL5 in solution to form a

gradient.

It is well established that HS constitutes the major component of the glycocalyx on the

endothelial cell surface(Oshima, King et al., 2021), and our earlier results showed that

degradation of endothelial surface HS by heparanase impaired the function of MIP-2/CXCL2

induced leukocyte rolling, adhesion and transmigration(Massena, Christoffersson et al., 2010).

From the finding of this study that the ratio of CCL5: heparin modulated droplets and

condensates formation (**Figure 1A and B**), we may assume that HS on the cell surface should

have a sufficient capacity to interact with chemokines, controlling their chemotactic activity

and inflammatory cell migration. This assumption is supported by the finding that

overexpressing CCL5 in CHO-K1 cells led to higher chemotactic activity, which may represent

a scenario of acute inflammatory reaction.

Collectively, our studies provide the first evidence that CCL5 gradient formation and chemotactic activity are dependent on HS. The interaction between CCL5 and HS is through a weak multivalent electrostatic binding, which facilitates LLPS and diffusion of the chemokine (**Figure 7**). Notably, the results suggest that there may exist a physiological balance between CCL5 and HS, modulating the chemokine activity. This finding supports the hypothesis to develop chemokine-binding HS-mimetics that may competitively interfere with the HS-chemokine binding and phase separation, accordingly modulating inflammatory reactions.

Materials and Methods

Key Resources Table				
Reagent type(species)or resource	**Designation**	**Source or reference**	**Identifiers**	**Additional information**
Gene (Homo-sapiens)	CCL5	GenBank	HGNC:10632	
strain, strain background (Escherichia coli)	Rosetta(DE3)	Biomed	BC204-01	
strain, strain background (Escherichia coli)	OrigamiB(DE3)	Biomed	BC205-01	

sequence-based reagent	[44]AANA[47]-CCL5-mut-F	(Ynebrten et al., 2015)	PCR primers	GCAGTCGTCTTTGTCACCGCGGCGAACGCGCAAGTGTGTGCCAACCCA
sequence-based reagent	[44]AANA[47]-CCL5-mut-R	(Ynebrten et al., 2015)	PCR primers	TGGGTTGGCACACACTTGCGCGTTCGCCGCGGTGACAAAGACGACTGC
Recombinant DNA reagent	pET-28a	Miao Ling Plasmid	P51040	
Chemical compound, drug	Cy3-NHS	ATT Bioquest	1023	
Chemical compound, drug	heparin	GlycoNovo	C-HEPPIM	Mw:13.980 Da
cell line (Homo-sapiens)	HUVEC	Pricella	CL-0675	
Cell ine(Cricetulus griseus)	CHO-K1	GlycoNovo		

Cell ine(Cricetulus griseus)	CHO-677	GlycoNovo		
biological sample(Mus musculus)	BALB/cAnN Crl	Vital River	211	female
biological sample(Homo-sapiens)	Human peripheral blood cell	China-Japan Friendship Hospital		Freshly isolated from volunteers
software, algorithm	CHARMM-GUI	CHARMM-GUI	RRID:SCR _025037	
software, algorithm	GROMACS	GROMACS	RRID:SCR _014565	
software, algorithm	gmx_MMPB SA	GitHub	RRID:SCR _002630	
software, algorithm	LAS X software 3.5	Leica Application Suite X	RRID:SCR _013673	

277 **Protein expression and purification**

DNA sequences of wild-type human CCL5 were synthesized by General Biosystems, China.

For the mutant of CCL5 ([44]AANA[47]-CCL5), site-directed mutations were introduced using the

Quikchange mutagenesis kit (Beyotime Biotechnology, China) using mutagenesis primes: 5'-

GCAGTCGTCTTTGTCACCGCGGCGAACGCGCAAGTGTGTGCCAACCCA-3'.   CCL5

gene and [44]AANA[47]-CCL5 gene were constructed in pET-28a vector (Miao Ling Plasmid,

China) and transformed into *E.coli* Rosetta (DE3), (Biomed, China) for expression(Proudfoot

et al., 1996, Proudfoot & Borlat, 2000). The products contained an additional Met residue at the

N-terminus (Met-CCL5) and His tag or EGFP-fusion protein. Bacterium were grown to optical

density of 0.6 at 37 °C and induced with 0.5 mM isopropyl-β-d-thiogalactopyranoside (IPTG)

at 37 °C for 5 h. The cells were harvested by centrifugation (4000 rpm, 20 min at 4 °C),

resuspended in lysis buffer (25 mM Tris-HCl, 100 mM NaCl, pH 8.0) and disrupted by

sonication. The cell lysate was centrifuged at 12000 rpm for 35 min at 4 °C. To recover the

recombinant CCL5 and [44]AANA[47]-CCL5 proteins that were mainly distributed in the inclusion

bodies, the pellet was collected and resuspended in denaturing buffer (100 mM Tris-HCl, 6 M

guanidine-HCl, pH 8.0) and disrupted by sonication. Cell debris was removed by centrifugation

($30000 \times g$, 20 min at 4 °C). The proteins in the supernatant were refolded by dialysis in to

refolding buffer (0.9 M guanidine-HCl, 100 mM Tris-HCl, 5 mM methionine, 5 mM cysteine,

pH 8.0). After repeated change of dialysis buster, the protein debris was removed by

centrifugation ($30000 \times g$, 20 min at 4 °C) and the supernatants were applied to His-Trap

chelating column (GE Healthcare), washed by refolding buffer and eluted with the same buffer

containing 30 mM imidazole. The purified proteins were dialyzed into 1.0 v/v% acetic acid

aqueous solution twice and finally into 0.1% v/v trifluoroacetic acid aqueous solution. The purity

of the recombinant CCL5 was analyzed by SDS-PAGE. After lyophilization, the CCL5 proteins

were dissolved in water and stored in −80 °C.

For a better folding, the CCL5-EGFP and [44]AANA[47]-CCL5-EGFP fusion proteins were

expressed in *E.coli* OrigamiB(DE3) and induced by 0.5mM IPTG at 25 °C for 12 h. The proteins

were purified by the same procedure as above.

Labeling of CCL5 with Cy3

Cy3 monosuccinimidyl ester (Cy3-NHS; ATT Bioquest, USA) was mixed with CCL5 to a final

concentration of 1.5 mg/mL, pH 9 adjusted with 1M $NaHCO_3$. The mixture was incubated with

shaking at 37 °C for 1 h, and then dialyzed in a 10 kDa dialysis tube (Thermo Fisher, USA) in

ddH_2O. These Cy3-labled CCL5 was mixed with un-labeled protein at 1:40 -1:20 ratio. This

dilution of the labeled protein is in consideration that N-terminus of CCL5 may be labeled with

Cy3, which is known to affect the activity of the protein.

Cell culture

Human Umbilical Vein Endothelial Cells (HUVEC) were cultured in Dulbecco's modified

Eagle's medium (DMEM) 1× with glucose (4.5 g/L), 10% fetal bovine serum (FBS), and 1%

antibiotics (penicillin/streptomycin). CHO-K1/CHO-677 cells were cultured in F12K medium

containing 10% FBS and 1% antibiotics. THP-1 were cultured in RPMI1640 medium

containing 10% FBS and 1% antibiotics. All cells were cultured at 37 °C with 5% CO_2 in a

humidified incubator.

Phase separation of CCL5 on cell surface

Cells were plated onto an eight-well Lab-Tek chambered coverglass (Thermo Fisher, USA) to

around 70% confluency. Before imaging, the medium was discarded, and the cells were washed

with PBS twice. Then, the protein solution diluted in the culture medium (500 nM) was added

to the cells and incubation 1 hr in a cell incubator. Confocal microscopy image was captured

with an inverted Leica DMi8 microscope, equipped with lasers for 489 nm, 554 nm excitation.

Images were acquired using a 63×objective (oil immersion).

Z-stack for Living Cell 3-D rendering

331 Three-dimensional reconstruction for living cells were implemented with an inverted Leica

332 DMi8 microscope. Images were acquired using the 63×oil immersion lens, a pinhole of 1 AU,

333 522 nm laser with 10% laser power, followed by setting the starting position and end position

334 of Z-stack, 100~200 Nr. of Steps or 1 μm z-step size was selected.

Imaging of CCL5 phase separation *in vitro*

CCL5 were diluted to 4-6 mg/mL in KMEI buffer (150 mM KCl, 1 mM $MgCl_2$, 1 mM

Ethylenebis (oxyethylenenitrilo) tetraacetic acid (EGTA) and 10 mM Imidazole, pH 6.5). For

the co-phase separation of CCL5 and heparin (GlycoNovo, China, Mw:13.980 kDa), 20 μM of

CCL5 were mixed with heparin and 5% w/v PEG-8000 in the assay buffer. The mixtures were

incubated at 37 °C for 30 minutes then were loaded into a 96-well plate for imaging analysis.

Images were captured with a Leica DMi8 confocal microscopy with a 63×objective (oil

immersion) and LAS X software 3.5.

Turbidity assay

346 CCL5 proteins were mixed with various concentrations of heparin (0~1000 μM) and PEG-8000

347 (5% w/v) in the KMEI buffer. After incubation at 37 °C for 30 minutes the mixture was

348 transferred to a 96-well plate and turbidity was measured by absorption at 620 nm using a

349 Multiskan FC microplate reader (Thermo Fisher, USA). All samples were examined in

350 triplicates (n = 3).

Molecular Docking

Heparin tetrasaccharide was docked to CCL5 (PDB number: 5coy) wild type and [44]AANA[47]-

CCL5 (PDB number: 1u4r) mutation by ClusPro server(Desta, Porter et al.). The docked models

were selected according to the following standards: (1) close to the critical residues, i.e., aa 44-

47, (2) having the lowest energy score. The selected CCL5-heparin tetrasaccharide complex

was handled by Glycan Reader & Modeler module of CHARMM-GUI (Damm, Wolfgang et

al., 1997, Gang, Liu et al., 2013) to set up the molecular dynamics simulation system and

generate the input files. The energy minimization (EM) simulations of the complexes were

performed with GROMACS [https://doi.org/10.1016/j.softx.2015.06.001], and based on the

EM trajectory, the binding free energy between CCL5 and heparin tetrasaccharide was

calculated with gmx_MMPBSA(Van Wart, Durrant et al., 2014).

Diffusion of CCL5 on heparin beads and Ni-NTA beads

Heparin beads (Solarbio, China) and Ni-NTA beads (GenScript, China) 50 μL gel were mixed

with 400 ng/μL of His-CCL5-EGFP and ^{44}AANA^{47}-CCL5-EGFP fusion proteins in a total

volume of 500 μL. After incubation for 30 min in ice, the beads were dropped into Matrigel

(ABWbionova, China) in 96-well plates kept on ice. Then the plates were moved to a 37 °C

incubator for 12 h. Images were captured with a Zeiss Axiocam 506 color Fluorescence

Microscope with a 5×, 10×objective and analyzed with ImageJ.

Chemotaxis assay

CHO-K1, mutant CHO-677 and HUVEC cells were cultured in the lower chamber of Transwell

with 8 μm pores (Corning, USA) with a density $1×10^5$ cells/well for 24 hr. Cells were washed

three times with PBS and then 500 nM CCL5 or the mixed solution of 500 nM CCL5 and

1mg/mL heparin (GlycoNovo, China) in culture medium were added and incubation 1 hr in a

cell incubator prior to the chemotactic assay. Then the THP-1 cells $(3×10^5)$ in RPMI1640

medium were placed onto upper chamber of Transwell and incubated for 4 hr in a cell incubator,

the transmigrated cells (in suspension) in the lower chamber were collected and counted by cell

counter and inverted microscope.

For chemotaxis assay using beads, CCL5-EGFP and [44]AANA[47]-CCL5-EGFP were first mixed

with the beads as described above, washed and diluted with PBS and then placed on the bottom

of lower chamber. The THP-1 cells were placed in the upper chamber. Cell migration analysis

was performed as described above.

Diffusion of CCL5-EGFP in cell surface

CCL5-EGFP was constructed in pCDNA3.1-EGFP vector (General Biosystems, China) and

transiently expressed in CHO-K1 cells. Briefly, the cells were seeded on 6-well plated at a

density of 2.5×10^5 cells/well in 2 mL medium for 24 hr and then transfected using Lipo8000^{TM}

Transfection Reagent (Beyotime Biotechnology, China). After 12 hr; transfected cells were

detached by pancreatin (2000/mL). HUVEC cells were plated onto an eight-well Lab-Tek

chambered coverglass (Thermo Fisher, USA) with a density 3×10^4 cells/well for 24 hr. The

transfected CHO-K1 cells (2000/mL) in 200 µL medium were added to the eight-well

coverglass coating HUVEC. After 1 hr, medium was aspirated and replaced with 50% of

Matrigel. The transfected CHO-K1 was co-cultured with HUVEC cells for 12 hr, and images

were captured with Leica DMi8 confocal microscopy with a 20×objective. For the capture of

droplets on cell surface and FRAP, the cellular membrane of HUVEC was stained with Dil (Cell

membrane red fluorescent probe, Beyotime, China) for 20 min and washed three times with

PBS. Images were captured with a 100×objective (oil immersion).

Human peripheral blood cell transmigration

Blood (1 mL) was collected from three healthy volunteers (We did not collect demographics)

in EDTA-tubes and centrifuged at 500×g (4°C for 5 min). After aspiration of plasma, the cells

were treated with 10 mL of Red Blood Cell Lysis solution (Beyotime Biotechnology, China)

for 10 min at 4°C and centrifuged. After removing supernatant, the cells were washed 3 times

with PBS, and resuspended in 400 µL of RPMI1640 medium and counted. The cell (denoted as PBMC) suspension (100 µL) was added to the upper chamber for the chemotaxis assay as described above. All blood samples were obtained with informed consent, and the study was approved by the ethics review committee of China-Japan Friendship Hospital (2022-KY-050). All relevant ethical regulations of China-Japan Friendship Hospital and governmental regulations were followed.

Recruitment of inflammatory cells in peritoneal lavage

Eight-week-old female BALB/c mice were purchased from Charles River and kept in a pathogen-free environment with fed ad lib. The procedures for care and use of animals were approved by Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park (SYXK-2021-0056) and all applicable institutional and governmental regulations concerning the ethical use of animals were followed. Mice were injected intraperitoneally with 200 µL of NaCl (0.9%, lipopolysaccharide-free), 1 mg/ml heparin, 500 nM wild-type CCL5, 500 nM ^{44}AANA^{47}-CCL5 or 500 nM wild-type CCL5 added by 1mg/mL heparin diluted into 200 µL of NaCl (0.9%, lipopolysaccharide-free), respectively. At 18 h post-injection mice were sacrificed by cervical dislocation, the cells in the peritoneal cavity were collected by lavage of 5 mL ice-cold PBS. The total cells collected were counted with automated cell counter (Bodboge, China).

Acknowledgments:

We thank Dr. Shuibing Chen and Dr. Yongxiang Chen for help editing the manuscript and the support from Beijing Advanced Innovation Centre for Soft Matter Science and Engineering is acknowledged.

Data and Materials availability statement: The authors confirm that the data supporting the

findings of this study are available within the article and supplementary file.

Funding

National Key R&D Program of China 2021YFC2103900 to SZL;

National Natural Science Foundation of China 22261132513, 22277009, 22077010 to SZL;

Joint Project of BRC-BC (Biomedical Translational Engineering Research Center of BUCT-

CJFH) (XK2023-14, XK2022-07) to SZL;

Swedish Research Council (2021-01094) to JPL;

Program of CPSF (GZC20230211) to PFP.

Conflict of interest

The authors declare that they have no conflicts of interest with the contents of this article.

References

Brandner B, Rek A, Diedrichs-Möhring M, Wildner G, Kungl AJ (2009) Engineering the
glycosaminoglycan-binding affinity, kinetics and oligomerization behavior of RANTES: a
tool for generating chemokine-based glycosaminoglycan antagonists. *Protein engineering,*
design & selection : PEDS 22: 367-73
Damm, Wolfgang, Frontera, Antonio, Tirado\uRives, Julian, Jorgensen, William, L. (1997)
OPLS all\u2010atom force field for carbohydrates. *J Comput Chem* 18: 1955-1970
Desta IT, Porter KA, Xia B, Kozakov D, Vajda S Performance and Its Limits in Rigid Body
Protein-Protein Docking. *Structure (London, England : 1993)* 28: 1071-1081.e3
Douglas, Dyer, Catherina, Salanga, Brian, Volkman, Tetsuya (2015) The dependence of
chemokine–glycosaminoglycan interactions on chemokine oligomerization. *Glycobiology*
Gang, Liu, Apurv, Puri, Sriram, Neelamegham (2013) Glycosylation Network Analysis
Toolbox: a MATLAB-based environment for systems glycobiology. *Bioinformatics (Oxford,*
England)
Ghosh A, Mazarakos K, Zhou HX (2019) Three archetypical classes of macromolecular
regulators of protein liquid–liquid phase separation. *Proceedings of the National Academy of*
Sciences 116: 201907849
Griffith JW, Sokol CL, Luster AD (2014) Chemokines and chemokine receptors: positioning
cells for host defense and immunity. *Annu Rev Immunol* 32: 659-702
Helen P. Makarenkova MPH, Andrew Beenken, (2009) Differential Interactions of FGFs with
Heparan

Sulfate Control Gradient Formation and

Branching Morphogenesis. *Sci Signal* 2: ra55

Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, Power CA, Wells TN

(1997) Glycosaminoglycans mediate cell surface oligomerization of chemokines.

Biochemistry 36: 13570-8

Horton M, Su G, Yi L, Wang Z, Xu Y, Pagadala V, Zhang F, Zaharoff DA, Pearce K,

Linhardt RJ, Liu J (2021) Construction of heparan sulfate microarray for investigating the

binding of specific saccharide sequences to proteins. *Glycobiology* 31: 188-199

Hyman AA, Weber CA, Jülicher F (2014) Liquid-Liquid Phase Separation in Biology. *Annual*

Review of Cell and Developmental Biology 30: 39-58

Kicheva A, Pantazis P, Bollenbach T, Kalaidzidis Y, Bittig T, Jülicher F, González-Gaitán M

(2007) Kinetics of morphogen gradient formation. *Science (New York, NY)* 315: 521-5

Liang, Wenguang G, Triandafillou, Catherine G, Huang, Teng-Yi, Zulueta, Medel ML,

Banerjee, Shiladitya (2016) Structural basis for oligomerization and glycosaminoglycan

binding of CCL5 and CCL3. *Proc Natl Acad Sci U S A* 113: 5000-5005

Lortat-Jacob H, Grosdidier A, Imberty A (2002) Structural diversity of heparan sulfate

binding domains in chemokines. *Proc Natl Acad Sci U S A* 99: 1229-34

Massena S, Christoffersson G, Hjertström E, Zcharia E, Vlodavsky I, Ausmees N, Rolny C, Li

JP, Phillipson M (2010) A chemotactic gradient sequestered on endothelial heparan sulfate

induces directional intraluminal crawling of neutrophils. *Blood* 116: 1924-31

Mulloy B (2005) The specificity of interactions between proteins and sulfated

polysaccharides. *Anais da Academia Brasileira de Ciencias* 77: 651-64

Nakashima KK, Vibhute MA, Spruijt E (2019) Biomolecular Chemistry in Liquid Phase

Separated Compartments. *Frontiers in molecular biosciences* 6: 21

Oshima K, King SI, McMurtry SA, Schmidt EP (2021) Endothelial Heparan Sulfate

Proteoglycans in Sepsis: The Role of the Glycocalyx. *Seminars in thrombosis and hemostasis*

47: 274-282

Proudfoot A, Fritchley S, Borlat F, Shaw JP, Wells T (2001) The BBXB motif of RANTES is

the principal site for heparin binding and controls receptor selectivity. *Journal of Biological*

Chemistry 276: 10620-10626

Proudfoot A, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, Wells T

(1996) Extension of Recombinant Human RANTES by the Retention of the Initiating

Methionine Produces a Potent Antagonist. *Journal of Biological Chemistry* 271: 2599-2603

Proudfoot AE, Borlat F (2000) Purification of recombinant chemokines from E. coli. *Methods*

in molecular biology (Clifton, NJ) 138: 75-87

Proudfoot AE, Handel TM, Johnson Z, Lau EK, Liwang P, Clark LI, Borlat F, Wells TN,

Kosco Vilbois MH (2003) Glycosaminoglycan binding and oligomerization are essential for

the in vivo activity of certain chemokines. *Proc Natl Acad Sci U S A* 100: 1885-1890

Proudfoot AEI, Johnson Z, Bonvin P, Handel TM (2017) Glycosaminoglycan Interactions

with Chemokines Add Complexity to a Complex System. *Pharmaceuticals (Basel,*

Switzerland) 10

Roscic-Mrkic B, Fischer M, Leemann C, Manrique A, Gordon CJ, Moore JP, Proudfoot AE,

Trkola A (2003) RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to

mediate cellular activation signals and HIV-1 enhancement. *Blood* 102: 1169-77

Roy A, Mondal S, Kordower JH, Pahan K (2015) Attenuation of microglial RANTES by

NEMO-binding domain peptide inhibits the infiltration of CD8(+) T cells in the nigra of

hemiparkinsonian monkey. *Neuroscience* 302: 36-46

Salanga CL, Dyer DP, Kiselar JG, Gupta S, Chance MR, Handel TM (2014) Multiple glycosaminoglycan-binding epitopes of monocyte chemoattractant protein-3/CCL7 enable it to function as a non-oligomerizing chemokine. *J Biol Chem* 289: 14896-912

Schier A, Needleman D (2009) Developmental biology: Rise of the source-sink model. *Nature* 461: 480-1

Shaw JP, Johnson Z, Borlat F, Zwahlen C, Kungl A, Roulin K, Harrenga A, Wells TN, Proudfoot AE (2004) The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors. *Structure* 12: 2081-93

Shi D, Zhao H, Bu C, Fraser K, Wang H, Dordick JS, Linhardt RJ, Zhang F, Shi F, Chi L (2023) New insights into the binding of PF4 to long heparin oligosaccharides in ultralarge complexes using mass spectrometry. *Journal of thrombosis and haemostasis : JTH* 21: 3608-3618

Simon Davis DA, Parish CR (2013) Heparan sulfate: a ubiquitous glycosaminoglycan with multiple roles in immunity. *Frontiers in immunology* 4: 470

Van Wart AT, Durrant J, Votapka L, Amaro RE (2014) Weighted Implementation of Suboptimal Paths (WISP): An Optimized Algorithm and Tool for Dynamical Network Analysis. *Journal of Chemical Theory & Computation* 10: 511-517

Weber M, Hauschild R, Schwarz J, Moussion C, Sixt M (2013) Interstitial Dendritic Cell Guidance by Haptotactic Chemokine Gradients. *Science* 339: 328-332

Xie M, Li JP (2019) Heparan sulfate proteoglycan - A common receptor for diverse cytokines. *Cellular signalling* 54: 115-121

Xue S, Gong R, He F, Li Y, Wang Y, Tan T, Luo S (2019) Low-complexity domain of U1-70K modulates phase separation and aggregation through distinctive basic-acidic motifs. *Science advances* 5: eaax5349

Xue S, Zhou F, Zhao T, Zhao H, Wang X, Chen L, Li J, Luo S (2022) Phase separation on cell surface facilitates bFGF signal transduction with heparan sulphate. *Nature communications* 13: 1112

Yamamoto T, Kambayashi Y, Otsuka Y, Afouda BA, Giuraniuc C, Michiue T, Hoppler S (2022) Positive feedback regulation of frizzled-7 expression robustly shapes a steep Wnt gradient in Xenopus heart development, together with sFRP1 and heparan sulfate. *Elife* 11

Ynebrten I, Barois N, Bergeland T, Küchler A, Haraldsen G (2015) Oligomerized, filamentous surface presentation of RANTES/CCL5 on vascular endothelial cells. *Sci Rep* 5: 9261

Yu SR, Burkhardt M, Nowak M, Ries J, Petrasek Z, Scholpp S, Schwille P, Brand M (2009) Fgf8 morphogen gradient forms by a source-sink mechanism with freely diffusing molecules. *Nature* 461: 533-6

Zbinden A, Pérez-Berlanga M, Rossi PD, Polymenidou M (2020) Phase Separation and Neurodegenerative Diseases: A Disturbance in the Force. *Developmental Cell* 55: 45-68

Figure 1 CCL5 phase separates with heparin in solution.

(A) Confocal images of assembling status of 20 µM CCL5-Cy3 mixed with heparin at different ratios and 5% PEG. Scale bar=10 µm. (B) Turbidity changes with increase of heparin concentration were measured at 620 nm (Figure 1-Source Data 1). (C) Fusion of phase-separated droplets formed at the ratio of CCL5-Cy3: heparin=1:2. The white arrows indicate the dynamic fusion of two adjacent droplets. (D) Representative FRAP results of droplets formed by CCL5-Cy3: heparin=1:2 depicted in Figure 1A, showing the intensity of fluorescence pre- and after photobleaching (Figure 1-Source Data 2). The images of representative droplets in different recovery stages are shown. (E) Confocal images of assembling status of [44]AANA[47]-CCL5 or CCL5 in the presence of heparin. Scale bar=10 µm. (F) Comparison of CCL5 and

559 [44]AANA[47]-CCL5 turbidity in the presence of heparin (Figure 1-Source Data 3). Data are mean

560 ± s.d. n=3 (for B, F). Normal distribution was assessed by the Shapiro-Wilk (SW) normality

561 test. *P* values were determined by unpaired two-tailed t-tests.

Figure 2 Co-phase separation of CCL5 and heparin establishes chemokine gradient

(A) CCL5-EGFP or ^{44}AANA^{47}-CCL5-EGFP were bound to heparin beads or Ni-NTA beads, respectively, and were placed in Matrigel in 96-well plate. After incubation for 12 hr images were taken to quantify the fluorescence intensity. (B) Quantification of the fluorescence signals along the lines with arrows indicated in Figure 2A (Figure 2-Source Data 1). (C) Illustration of *in vitro* chemotaxis assay. (D) Heparin beads or Ni-NTA beads bound with CCL5 or ^{44}AANA^{47}-CCL5 were placed in the lower chamber. THP-1 cells (3×10^5 cells) were added to upper chamber. After 4 hr, THP-1 in the lower chamber was collected and counted (Figure 2-Source Data 2). Data are mean ± s.d. n=3. Normal distribution was assessed by the Shapiro-Wilk (SW) normality test. *P* values were determined by unpaired two-tailed t-tests.

Figure. 3 CCL5 phase separates with heparan sulfate on the cell surface

(A) Microscopy images of CCL5-Cy3 on the surface CHO-K1 and CHO-677 as well as CHO-K1 treated with 1 mg/mL heparin. From left to right, the images are fluorescent-field, bright-field and overlay of two illuminations. Scale bar=10 μm. (B) Z-stack scanning of CCL5-Cy3 phase separation on CHO-K1 cell surface. The cell was imaged by confocal microscope with the Z-stack method. Scale bar=10 μm. (C) FRAP of the condensates formed by CCL5-Cy3, showing the intensity of fluorescence pre- and after photobleaching (Figure 3-Source Data 1).

The size of the representative droplets in different recovery stages are shown above of the graph.

(D) Graphical illustration of the cell-based chemotaxis assay. CHO cells (1×10^5 cells/well) were

plated onto the lower chamber for 24 h (fully attached) and CCL5 or ^{44}AANA^{47}-CCL5 or

heparin were added as indicated. THP-1 cells (3×10^5) were placed on upper chambers. After 4

hr, a small volume of medium in the lower chamber was aspirated to count THP-1 transmigrated

through the membrane. (E) Quantification of THP-1collected from the lower chamber (Figure

3-Source Data 2). Data are mean ± s.d. n=3. Normal distribution was assessed by the Shapiro-

Wilk (SW) normality test. *P* values were determined by unpaired two-tailed t-tests.

Figure 4 Formation of chemokine gradient on the cell surface by phase separation

(A) HUVEC cells were seeded on the plates for 24 h and stained with DiI (Cell membrane red fluorescent probe). After washing with PBS, CCL5-EGFP transfected CHO-K1 were added and co-cultured for 24 hr before taking the images (Scale bar=10 μm). (B) Fusion events of droplets formed by CCL5-EGFP on HUVEC cell surface. The white arrows in cropped images indicate the fusion of two droplets with time. (C) FRAP of the condensates formed by CCL5-EGFP in HUVEC cell surface, showing the intensity of fluorescence pre and after photobleaching (Figure 4-Source Data 1). The images of representative droplets in different recovery stages are shown. (D) HUVEC cells were seeded on the plate and firmly adhered before adding the 400 CCL5-EGFP transfected CHO-K1 cells placed in 50% of Matrigel. After 1 hr co-culture, confocal images were taking showing CCL5-EGFP diffusion on the surface of HUVEC. Dotted white

circle indicates the source cell of CCL5-EGFP transfected CHO-K1. Scale bar=100 μm. (E)

Quantification of the fluorescence intensity shows decreased signals of CCL5-EGFP as the

distance from the source cells increased (Figure 4-Source Data 2). (F) The chemotaxis assay

(same experimental conditions as described in Figure 1) shows higher activity of CCL5-EGFP

transfected CHO-K1 cells than wild type CHO-K1 cells (Figure 4-Source Data 3). Data are

mean ± s.d. n=3. Normal distribution was assessed by the Shapiro-Wilk (SW) normality test. *P*

values were determined by unpaired two-tailed t-tests.

Figure 5 Transmigration of human peripheral blood cells

The cells (CHO-K1, CHO-677, or HUVEC) (1×10^5 cells/well) as indicated were plated onto

the lower chamber for 24 hr (fully attached) and CCL5 was added for 1 hr. PBMC isolated from

three healthy volunteer donors were placed in the upper chamber (total number of cells: Sample

1: $8.65\wedge10^5$; Sample 2: $2.31\wedge10^6$; Sample 3: $2.23\wedge10^6$). After culturing for 4 hr, the total

transmigrated cells in the lower chamber were counted (Figure 5-Source Data 1).

Figure 6 Chemokines phase separation promotes cell recruitment in vivo. Mice were

treated by intraperitoneal injection of CCL5 or the reagents as indicated. After 18h, the animals

were sacrificed and peritoneal lavage was collected. Total cell number was counted by

automated cell counter (Figure 6-Source Data 1). Data are mean ± s.d. n=4. Normal distribution

was assessed by the Shapiro-Wilk (SW) normality test. *P* values were determined by unpaired

two-tailed t-tests.

Figure 7 Schematic model of CCL5 phases separation along with heparan sulfate on the cell surface. The inflammatory cells secrete chemokines that are immobilized by heparan sulfate in the form of Liquid-Liquid phase separation and subsequently diffused to form a concentration gradient.

Figure1—Figure supplement 1 Protein expression and purification.

(A)-(B) SDS-PAGE showed the molecular weight and purity of CCL5 (A) and CCL5-EGFP (B).

Figure 1—figure supplement 2 The effect of salt concentration on phase separation.

(A) Confocal images of assembling status of 20 μM CCL5-Cy3 mixed with heparin with increasing salt

concentration. Scale bar=10 μm.

(B) Turbidity changes with different increasing salt concentrations.

(C) Confocal images of assembling status of A22K-CCL5 or CCL5 in the presence of heparin. Scale bar=10

μm. (D) FRAP of the aggregates formed by A22K-CCL5-Cy3, showing the intensity of fluorescence pre- and

after photobleaching.

CCL5 and heparin tetrasaccharide   ⁴⁴AANA⁴⁷-CCL5 and heparin tetrasaccharide

647
Figure 1—figure supplement 3 Comparison of binding of CCL5 and ⁴⁴AANA⁴⁷-CCL5 to heparin
648
tetrasaccharide.
649

650 (A) Binding mode of heparin tetrasaccharide to ⁴⁴AANA⁴⁷-CCL5 or CCL5 shown by molecular docking. On the

651 right are the details framed by the dotted line. (B) Comparison of binding free energy of different interacting forces

652 between CCL5/⁴⁴AANA⁴⁷-CCL5 and heparin tetrasaccharide. The mutation led to change in electrostatic

653 interaction forces.

Figure 2—figure supplement 1 Chemotactic function of CCL5-EGFP.

Labeled CCL5 has similar activity as CCL5, 50 nM CCL5, CCL5-EGFP or CCL5-Cy3 were added to the lower chamber of the Transwell. THP-1 cells were added to upper chambers. Data are mean ± s.d. n=3. *P* values were determined by unpaired two-tailed t-tests. NS, Not Significant.

CCL5+Heparin beads   CCL5+Ni-NTA beads

Figure 2—figure supplement 2 Diffusion of the CCL5-Cy3 in heparin-beads or Ni-NTA beads. Beads

bound with CCL5-Cy3 placed in Matrigel were imaged and reconstructed by Leica DMi8.

668　**Figure 3—figure supplement 1 ^{44}AANA^{47}-CCL5 didn't immobilize to the surface of CHO-K1.** CHO-

669　K1 were treated with 500 nM ^{44}AANA^{47}-CCL5. From left to right, the pictures showed bright-field,

670　fluorescent-field and overlay of two illuminations.

672
Figure 4—figure supplement 1 Diffusion of CCL5-EGFP on cell surface.

(A) Confocal images of Transfected CHO-K1 and HUVEC cells. Scale bar=100 μm. The yellow boxes are

shown in higher magnification on the right. Scale bar=10 μm. CCL5-EGFP was expressed by transfected

CHO-K1 and then adhere to the surface of HUVEC and formed phase separation. (B) The range of CCL5-

EGFP diffusion on HUVEC cell surface at different time. The black dashed box showed the final image size.

(C) Fluorescence intensity along the dotted lines indicated in Figure 4—figure supplement 1B. (D) Confocal

images of Transfected CHO-K1 and CHO-K1 or CHO-677. CCL5-EGFP was expressed by transfected CHO-

K1 and then adhere to the surface of CHO-K1 and formed phase separation but CHO-677 completely lack

the signals. Scale bar=25 μm.